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Abstract: The twofold role of autophagy in cancer is often the therapeutic target. Numerous regula­
tory pathways are shared between autophagy and other molecular processes needed in tumorigenesis, 
such as translation or survival signaling. Thus, we have assumed that ILK knockdown should pro­
mote autophagy, and used together w ith chloroquine, an autophagy inhibitor, it could generate a 
better anticancer effect by dysregulation of com mon signaling pathways. Expression at the pro­
tein level was analyzed using Western Blot; siRNA transfection was done for ILK. Analysis of cell 
signaling pathways was monitored w ith phospho-specific antibodies. Melanoma cell proliferation 
was assessed with the crystal violet test, and migration was evaluated by scratch wound healing 
assays. Autophagy was monitored by the accumulation of its marker, LC3-II. Our data show that ILK 
knockdown by siRNA suppresses melanoma cell growth by inducing autophagy through AM PK 
activation, and simultaneously initiates apoptosis. We demonstrated that combinatorial treatment of 
melanoma cells w ith CQ  and siILK has a stronger antitumor effect than monotherapy with either 
of these. It generates the synergistic antitumor effects by the decrease of translation of both global 
and oncogenic proteins synthesis. In our work, we point to the crosstalk betw een translation and 
autophagy regulation.
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1. Introduction
The key role played by autophagy in cancer is undisputed, but whether it is tumor- 
suppressive or tumor-promoting remains a controversial matter. Autophagy can suppress 
the initiation and development of a tumor, but on the other hand, it is employed by the 
tumor for adaptation to stress or starvation, and in response to cancer therapies [1,2]. 
Autophagy is essential for survival and development because it is a homeostatic cellular re­
cycling pathway for degrading damaged or unnecessary proteins or even whole organelles. 
Low levels of autophagy maintain cell homeostasis by eliminating damaged molecules or, 
in the case of starvation, by supplying amino acids from degraded proteins [3]. In cancer 
biology, autophagy plays a dual role in cell survival and cell death. On the one hand, 
autophagy inhibits the growth and development of cancer, and on the other, it allows it 
to survive during chemotherapy [1- 6] . Cancer cells are more autophagy-dependent than 
normal cells, thus, targeting autophagy is a therapeutic strategy for cancer therapy [4- 6]. In 
melanoma, autophagy plays a dual role in cell survival and cell death. It has been shown 
that autophagy by itself suppressed melanogenesis and in addition it was reported that 
inhibition of autophagy may play a tumor-suppressing role. In the early stage of melanoma 
and other cancers, autophagy inhibits the tumor process, whereas in the advanced stage 
it seems to be an adaptive mechanism and acts as a tumor survival mechanism or even a 
tumor promoter [2,7].
Autophagy is regulated by mTOR, AMPK, and extracellular signals regulating kinase 
ERK. mTOR is a major cell-growth regulator controlling the expression of cellular proteins 
by integration signals from growth factors and nutrients. Under nutrition-rich conditions
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or in the presence of growth factors signals, mTOR inhibits autophagy. The AMP-activated 
protein kinase (AM PK) promotes autophagy in response to the low energy of glucose 
deprivation. AMPK is also known to stimulate autophagy by inhibition of mTORC1 in a 
TSC-dependent manner or by direct phosphorylation of RAPTOR, an essential component 
mTORC1 complex. ERK is a downstream effector of MAPK and BRAF signaling. Common 
BRAFV600E mutation in melanoma results in hyper-activation of the M APK/ERK pathways, 
which correlates with MNKs-associated increase of phosphorylation of eIF4E, and favors 
tumorigenesis. The use of BRAF inhibitors develops a stress response— autophagy as 
a mechanism of drug resistance in melanoma cells. Thus, induction of disturbances in 
the autophagy process seems to be a promising melanoma treatment strategy in either a 
monotherapy or a combination therapy [8]. Chloroquine, which is a well-known antimalar- 
ial drug, increases the pH of lysosomes and effectively inhibits fusion of autophagosomes 
and lysosomes, thus interfering with protein degradation [9]. It is a well-accepted view that 
chloroquine (CQ) efficiently inhibits autophagy, and also shows promise for cancer treat­
ment. The anti-cancer effect of chloroquine has been observed both in vitro and in vivo, in 
monotherapy as well as in combination with conventional anti-cancer treatments according 
to a new clinical study published in ecancermedicalscience [10]. Apart from autophagy 
inhibition, the pharmacological anti-cancer profile of chloroquine appears to also involve 
other mechanisms such as inhibition of proliferation, induction of apoptosis, or influencing 
tumor vasculature [11- 14].
The multi-faceted anti-cancer action of CQ makes this drug attractive for cancer 
therapy. Recent reports show that combination treatment with autophagy inducers and 
inhibitors in cancer cells enhance the effect of anti-cancer therapies [8,15]. The sensitivity 
of melanoma cells to chloroquine was shown as independent of the BRAF mutation sta­
tus [16]. For this reason, we decided to use CQ, which has been reported to exert anticancer 
effects on melanoma and other tumors [11,12,16], in combination with silencing of ILK 
(integrin-linked kinase) to strengthen siILK-caused inhibition of pro-survival signaling 
with CQ-driven autophagy inhibition. ILK takes part in various cell functions, such as cell- 
extracellular matrix interactions, cell cycle, apoptosis, cell proliferation, cell motility, and 
induction of epithelial-mesenchymal transition (EMT), which are related to the interacting 
partners of ILK and downstream signaling pathways [17,18]. We demonstrated that inhibi­
tion of ILK expression and activity using siRNA has antitumor effects in melanoma and 
bladder cancer [19- 21]. ILK is a critical regulator of the cancer-survival pathway, including 
PI3K/AKT, glycogen synthase kinase 3ß (GSK3ß), nuclear factor-kappaß (NF-Kß), mTOR, 
or Snail1/E-cadherin/N-cadherin [20,22,23]. Since PI3K/A kt/m TO R axis activation results 
in autophagy inhibition [24], we assume that the knockdown of ILK promotes autophagy.
We have previously shown that ILK silencing has anti-tumor implications for both 
melanoma and bladder cancer [19,20]. The present study is aimed at exploring the effects 
of CQ alone or in combination with silencing of ILK on melanoma cells and pathways 
associated with these treatments, as well as identifying potential molecular targets for 
melanoma treatment.
2. Results
2.1. Silencing o f  ILK and Chloroquine Inhibits the Survival o f Melanoma Cells
Elevated ILK expression and activity contributes to increased proliferation and inva­
sive potential of melanoma cells [19,25]. ILK knockdown reduced cell viability in both cell 
lines by about 25% in comparison to control cells (Figure 1A,B). Chloroquine also inhibits 
the growth and survival of melanoma cells to a similar extent as ILK silencing (Figure 1A,B). 
Simultaneous use of siRNA for ILK and chloroquine markedly affected cell growth and 
showed a 40% reduction in cell viability (Figure 1B). The increased level of cleaved Poly 
(ADP-ribose) polymerase (PARP1) indicates that apoptosis may contribute to cell death 
after silencing of ILK at least in WM793 and early-stage melanoma cells (Figure 1C). PARP1 
plays a role in DNA repair; it is activated by binding to DNA ends or strand breaks. The 
cleavage of PARP1 catalyzed by caspase-3 causes inactivation of PARP1 [26].
Figure 1. The inhibitory effect of ILK knockdown and CQ use on the survival of melanoma cells. 
" + "  refers to siRNA ILK or chloroquine; " —"  refers to silencer negative control cells. All results 
are presented as % of control; asterisk (*) indicates a significant difference: * p  < 0.05, ** p  <  0.01, 
*** p  <  0.001. (A)— the expression of ILK after silencing detected by Western blotting in the presence 
or absence of CQ. (C)— Effect of ILK knock-down and CQ use on cleaved PARP-1. Representative 
blots are displayed and quantitative representation of data after densitometry (mean ±  SD) of three 
independent experiments on histograms. B-actin was used as a protein loading control. (B)— Cell 
proliferation w as assessed w ith the crystal violet test. Values are expressed as m ean ±  standard 
deviation in 6 wells in three independent experiments.
2.2. Knockdown o f  ILK-InducedAutophagy
During autophagy, LC3 (microtubule-associated protein light chain 3) is cleaved off by 
Atg4 (cysteine protease) generating LC3-I, which is conjugated to phosphatidylethanolamine 
to form LC3-II. While LC3-I stays in the cytoplasm, LC3-II binds to both the outer and the 
inner membranes of the autophagosome [27]. We examined if silencing of ILK by siRNA 
affects LC3-II level used as a marker of autophagy progression. Both studied melanoma 
cells exhibit a high level of basal autophagy but respond differently to the knockdown of 
ILK. After silencing of ILK, WM793 cells accumulated LC3-II similarly to the CQ treatment 
(Figure 2A). In 1205Lu, we observed an uptick in LC3-II levels not comparable with the CQ 
effect, and a decrease in LC3-I form (Figure 2A). The knockdown of ILK seems to activate 
autophagy more in the early stages of melanoma development than in metastatic cells.
Figure 2. Effect of ILK knockdown on autophagy induction. " + "  refers to siRNA ILK or chloroquine; 
" —"  refers to silencer negative control cells. The expression of (A)— LC3-II, both phosphorylated 
and total (B)— AM PK, (C)— ULK1 were determined by  Western blotting. Representative blots are 
displayed. The histograms are a quantitative representation of data after densitometry (mean ±  SD) 
of three independent experiments. ß-actin was used as a protein loading control. Asterisks indicate 
significant differences from control cells. Values are denoted as * p <  0.05, ** p <  0.01, and *** p < 0.001.
2.3. ILK Inhibits AMPK-Dependent Autophagy
Autophagy is promoted by AMP-activated protein kinase (AMPK) as an energy re­
ceptor. Activation of AMPK by phosphorylation at Thr172 in catalytic subunit a  promotes 
autophagy initiation as the major regulator. Phosphorylation of the AMPK a-subunit at 
Thr172 is controlled by upstream kinases: liver kinase B1 (LKB1) and calcium/calmodulin- 
dependent protein kinase-ß (CaMKKß). Furthermore, the A kt/G SK  signaling pathway 
is involved in the regulation of AMPK activity. GSK3 binds with AMPKß prior to phos­
phorylation of AM PKa, which facilitates AM PKa binding to phosphatases, and therefore 
inactivates AMPK. Akt signaling normally inhibits GSK3 activity, promotes GSK3 phospho­
rylation at S9, and in effect leads to inhibition of AMPK [28]. Phosphorylation of AMPK 
was also observed in chloroquine treatment in myotubes [29]. We showed earlier that 
in cancer cells, ILK phosphorylates and activates Akt at Ser 473. ILK also directly phos- 
phorylates GSK-3ß at Ser 9, thus inactivating it [19,20]. siRNA-mediated ILK knockdown 
resulted in the activation of AMPK by its increased phosphorylation at Thr172, which 
was significant in WM793, and not as substantial in 1205Lu (Figure 2B). The increase of 
phosphorylation of AMPK is also visible after CQ treatment alone as well as in combination 
with siILK (Figure 2B).
2.4. ILK Knockdown is Sufficient to Induce Autophagy Through Regulation ofU LK1 Activity
ULK1 is a critical mammalian autophagy-initiating Ser/T h r kinase necessary for
U LK 1/A tg13/FIP200 complex formation. The activated ULK complex localizes to the 
phagophore and activates the PI3K complex responsible for nucleation of the next phase 
of autophagy processes. The ULK complex formation in a phosphorylation-dependent 
manner is suppressed by mTORC1. The active mTORC1 phosphorylates S757 and pre­
vents ULK1 interaction with the rest of the complex [30]. W hen mTORC1 is inhibited, 
dephosphorylated ULK1 at S757 forms an active complex with Atg13 and FIP200. ULK1 
can also be directly phosphorylated by AMPK at a site distinct from the mTORC1 one. 
The AMPK-phosphorylated ULK1 at S317, S777, and S555 is active and able to initiate 
autophagy. ULK1 can interact with and be activated by AMPK only when mTORC1 phos­
phorylation of S757 is decreased [31]. As shown in Figure 2C, ILK knockdown decreased 
ULK1 phosphorylation at S757, which probably enabled its interaction with AMPK in the 
melanoma cell line WM793. In the more advanced melanoma cell line 1205Lu, we observe 
a markedly higher increase of ULK expression after silencing of ILK. Moreover, activation 
of ULK1 by AMPK is visible as increased phosphorylation on S555 in comparison to control 
cells (Figure 2C). These data indicate that ILK likely regulates autophagy through the 
coordinate activity of mTORC1 and AMPK.
2.5. mTOR Activity Regulated by ILK and Chloroquine
mTOR, together with its pathway components, is known as a negative regulator 
of autophagy. mTOR forms two multi-protein complexes because mTOR kinase can be 
associated with various regulatory proteins. mTORC1 is defined by RAPTOR (regulatory- 
associated protein of mTOR), while mTORC2 is determined by RICTOR (rapamycin- 
insensitive companion of mTOR). mTORC1 is activated by the Akt pathway and integrates 
signals from outside the cell with the translational machinery. mTORC2 is involved in 
cell cycle progression and cell survival by phosphorylation of S473 on Akt [24]. We found 
that the WM793 cell line has more RAPTOR than RICTOR protein, but the exact opposite 
is the case with the 1205 Lu cell line (Figure 3A ). The expression of these proteins drops, 
especially after CQ treatment alone or in combination with siRNA for ILK, but only in the 
WM793 cell line. In 1205 Lu cells, we observed a marked increase in expression in RICTOR, 
in particular after silencing of ILK or chloroquine treatment, as well as simultaneous use of 
both (Figure 3B). The decreased phosphorylation status of S2448 specific for mTORC1 was 
visible in 1205Lu cells after their treatment with chloroquine alone or in combination with 
siRNA for ILK, but not for the latter used alone. Increased mTOR kinase protein level is 
accompanied by increased S2481 phosphorylation specific for mTORC2 in this line after 
silencing of ILK or CQ treatment, but when both were used simultaneously, the activity 
of both mTORC2 and mTORC1 decreased. On the contrary, a marked decrease of S2481 
phosphorylation (mTORC2) was noted in WM793 cells after ILK silencing, chloroquine 
treatment, or simultaneous use of both. Additionally, we observed a slight increase of the 
mTOR protein level, which co-occurred with a S2448 phosphorylation (mTORC1) increase 
in cells with knocked down ILK (Figure 3C). The surprising results of the cell response may 
stem from the a priori different expression of RICTOR and RAPTOR in the tested lines.
Important targets of mTORC1 in translational control are 4E-BP1 (eukaryotic transla­
tion initiation factor 4E-binding protein) and p70S6K (ribosomal protein p70S6 kinase) [24]. 
The basal expression levels of p70S6K decreased significantly after silencing of ILK and 
drastically after CQ treatment alone or in combination with siRNA for ILK in both studied 
cell lines. This effect was not consistent with the phosphorylation status. Phosphorylation 
of Thr389 induces a conformational change that exposes Thr229 in the activation loop of 
p70S6K and allows its phosphorylation by PDK1, resulting in p70S6K activation [32].
Figure 3. Effect of ILK knockdown and CQ use on mTOR activity. " + "  refers to siRNA ILK or 
chloroquine; " —" refers to silencer negative control cells. (A)— Expression RICTOR and RAPTOR. 
Representative blots are displayed. The histogram  presented protein level expression. (B)— The 
histogram  presented relative protein expression level after densitom etry (mean ±  SD) of three 
independent experiments. ß-actin was used as a protein loading control. Asterisks indicate significant 
differences from control cells. Values are denoted as * p <  0.05, ** p <  0.01, and *** p <  0.001. 
(C)— the expression of both phosphorylated and total mTOR. Representative blots are displayed. 
The histogram s are a quantitative representation of data after densitom etry (mean ±  SD) of three 
independent experiments. ß-actin was used as a protein loading control. Asterisks indicate significant 
differences from control cells. Values are denoted as * p <  0.05, ** p <  0.01, and *** p <  0.001.
The phosphorylation on Thr 389 p70S6 decreased insignificantly only when ILK and 
CQ were used simultaneously. W hen either CQ or siRNA for ILK were used indepen­
dently, the p70S6K activity monitored as its phosphorylation on Y389 has even increased 
(Figure 4A ). The unexpectedly higher phosphorylation in relation to the reduced amount 
of protein results from the fact that p70SK is a protein not exclusively phosphorylated by 
mTOR, but also phosphoinositide 3-kinase (PI3K) signaling, mitogen-activated protein 
kinase (MAPK) signaling, and even p70S6K autophosphorylation [32].
In the case of ribosomal protein S6, a substrate for p70S6K, we detected that the 
decrease in protein expression was accompanied by a decrease in phosphorylation in the 
W M793 and 1205 Lu cells treated with CQ alone or in combination with siRNA for ILK. 
We noticed increased expression as well as the phosphorylation level of rpS6 in 1205 Lu 
after knockdown of ILK (Figure 4B). Another important substrate of mTORC1 is 4E-BP1, a 
small translational repressor, which after phosphorylation by mTORC1 releases eIF4E. Our 
results showed increased repression activity of 4EBP1 in response to ILK silencing or CQ 
treatment only in WM793, and their simultaneous use was more effective when compared 
to monotherapy in both tested cell lines (Figure 4C). CQ use in monotherapy in 1205Lu
cells caused a very significant increase of the hyper-phosphorylated form 4EBP1, which 
weakens its interaction with eIF4E (Figure 4C).
The main known mTORC2 activity is the phosphorylation and activation of Akt, but 
it is not the only factor activating this critical cell fate upstream kinase [33]. We showed 
that kinase ILK can also activate the Akt [19,20]. Therefore, it comes as no surprise that the 
activation of Akt decreases upon ILK silencing alone or in combination with CQ. Reduction 
of basal expression of Akt resulted in downregulation of pAkt in W M793 treated with 
CQ alone or in combination with siRNA for ILK, and the decrease of Akt activity was 
more prominent in the case of simultaneous use of both. However, treatment with CQ 
alone resulted in an increased Akt activity in 1205Lu, a metastatic melanoma cell line. A 
relatively higher level of phosphorylation of Akt in 1205Lu in the presence of CQ suggests 
a higher activity of mTORC2 in these cells (Figure 4D).
Figure 4. The effect of ILK silencing and CQ use on downstream of the mTOR signaling pathway. "+ "  
refers to siRNA ILK or chloroquine; " —" refers to silencer negative control cells. Protein expression, 
both phosphorylated and total, was assessed by Western blotting. Representative blots are displayed. 
The histogram s are a quantitative representation of data after densitom etry (mean ±  SD) of three 
independent experiments. ß-actin was used as a protein loading control. Asterisks indicate significant 
differences from control cells. Values are denoted as * p <  0.05, ** p <  0.01, and *** p <  0.001. (A)—  
ribosomal protein p70S6 kinase, (B)— ribosomal protein S6, (C)— eukaryotic translation initiation 
factor 4E-binding protein (4E-BP-1)-phosphorylated form, (D)— Akt expression.
2.6. Targeting the Translational Machinery by Silencing ILK, CO, and Combination Treatment
Cancer cells require elevated protein synthesis as com pared to their norm al counter­
parts. Tum origenesis is highly influenced by regulation of the cap-dependent translation, 
w hich needs the eukaryotic translation initiation factor 4F complex. A very im portant part 
of this com plex is eIF4E [34]. We detected quite a pronounced expression level of eIF4E in 
both the melanoma cell lines. Both CQ and siRNA for ILK, whether they were used solo or 
in tandem , decreased the basal level of protein eIF4E significantly, however, most effective 
in both lines was their combination (Figure 5A ). Phosphorylation of eIF4E on S209 is tightly 
regulated by MNK1 / 2  kinases and plays an im portant role in the translational activity of 
eIF4E [35,36], In the W M 793 cell line, the decrease in eIF4E expression is accompanied by a 
decrease in S209 phosphorylation (Figure 5A). W hereas a drop in phosphorylation on S209 
was detected in all cases in 1205Lu, a very significant decrease was observed only after the 
application of ILK silencing. The maintenance of phosphorylation on S209 in 1205Lu seems 
to be a consequence of an increase in the activity of MNK1 kinase in the presence of CQ or 
silencing of ILK. A high level of phospho-M nk 1 was also observed after ILK silencing in 
the W M 793 cell line (Figure 5B).
Figure 5. The inhibitory effect of ILK knock-down and CQ use on translation melanoma cells. " + "  
refers to siRNA ILK or chloroquine; " —"  refers to silencer negative control cells. The expression 
of both phosphorylated and total proteins was determined by Western blotting and representative 
blots are displayed. The histogram s are a quantitative representation of data after densitom etry 
(mean ±  SD) of three independent experiments. ß-actin was used as a protein loading control. 
Asterisks indicate significant differences from control cells. Values are denoted as* p < 0 .0 5 ,**  p <0 .01 , 
and *** p  <  0.001. (A)— eukaryotic translation initiation factor 4F (eIF4E), (B)— MNK1 kinase, (C)— 
eukaryotic initiation factor eIF2a.
Another key component of translational machinery is eukaryotic initiation factor eIF2, 
the role of which is to supply the initiator tRNA to the ribosome. Phosphorylation of the 
a  subunit of eIF2 on S51 attenuated the general protein translation while facilitating the
translation of selected proteins such as transcription factor ATF4 [37], The use of either CQ 
or siRN A  for ILK, as w ell as both  of them  sim ultaneously significantly reduced the basic 
level of the eIF2oc subunit, and also lowered the level of phosphorylation but not as visibly 
as the total level of protein (Figure 5C ).
2.7. Migration
To evaluate the effects of CQ and knockdow n of ILK on m elanom a cell m igration, 
w e perform ed a scratch w ound healing assay  In our previous w ork, w e show ed that 
ILK silencing reduces the m igration of m elanom a cells in the Boy den cham ber [19] and 
also decreases transendothelial cell m igration [21]. We adopted an in vitro w ound heal­
in g / m igration assay for evaluation of the potential enhancem ent of the anti-cancer effect 
of silLK  by using it together w ith CQ. The results show  that silencing of ILK significantly 
reduced (by about 60%) wound closure after 24 h in both melanoma cell lines. We observed 
a slight supporting effect of CQ treatm ent on reduction of m igration in 1205Lu but a 
significant effect in W M793 (58%). In the case of combination treatm ent with CQ and silLK, 
the m igration reduction effect is maintained at the level of siRNA for ILK treatm ent results 
(Figure 6) .
Figure 6. The effect of ILK knock-down and CQ use on in vitro wound healing/m igration assay. 
After 24 h, the confluent cell monolayer was wounded and wound closure was captured by a digital 
camera connected to the inverted microscope. The assay was repeated thrice in duplicate. The 
area of w ound closure was measured with the use of ImageJ and expressed as the percentage of 
wound closure. Asterisks indicate significant differences from control cells. The histograms are 
a quantitative representation of data (mean ±  SD) of three independent experiments. Values are 
denoted as * p <  0.05, ** p <  0.01, and *** p <  0.001.
3. Discussion
In our study, we demonstrated that silencing of ILK induced autophagy much more 
frequently in the early stage of melanoma compared to metastatic, and it may lead in­
dependently to cell death or act as a precursor of apoptosis. Our previous studies have 
revealed the important role of ILK in melanoma EMT and particularly in the regulation of 
N-cadherin expression by modulation of the expression of Rab proteins associated with 
N-cadherin endocytosis, degradation, or recycling. The observed increase in Rab9 expres­
sion after ILK silencing suggested that ILK may be in part responsible for the regulation of 
autophagy [21]. The overexpression of ILK inhibits autophagy by activation of Akt and 
mTOR [38] . On the other hand, autophagic disruption of E-cadherin/ß -catenin interaction 
promotes EMT by upregulation of ILK [39]. It was reported that EMT-connected signaling 
pathways influence autophagy. The complicated link between autophagy and EMT seems 
to be a good target for cancer treatment [40]. Inhibition of endogenous autophagy by CQ 
is related to decreased cell survival in both herein-studied melanoma cell lines. These 
results remain in agreement with data showing that CQ is effective in growth inhibition 
in a variety of cancers, including melanoma, oral squamous cell carcinoma, or bladder 
cancer [11,12,16]. Apart from autophagy inhibition, the anti-cancer profile of chloroquine 
also involves mechanisms such as inhibition of proliferation, induction of apoptosis, or 
influencing tumor vasculature [11- 14].
The crucial reason for the decrease of melanoma cells survival is probably the decline 
in the rate of translation by the decrease in expression of eukaryotic translation initiation 
factors such as eIF4E and eIF2a, observed after silencing of ILK and CQ treatment as well 
as the simultaneous use of both. Cancer cells require elevated protein synthesis, espe­
cially proteins necessary for an invasive phenotype. Both global protein synthesis and the 
selective translation of oncogene mRNAs are necessary for tumor growth, proliferation, 
and survival [34]. The crosstalk between translation and autophagy is disturbed in can­
cer [41]. The translation of tumor-associated proteins is controlled by mitogen-activated 
translational factor eIF4E, the expression of which is elevated in cancer cells [42]. Its 
availability and activity are controlled by mTORC1 through regulation of eIF4E inhibitor 
(4E-BP1) and M NK1/2 kinase, which phosphorylates eIF4E on S209. Phosphorylated eIF4E 
(peIF4E) preferentially enhances expression of oncogenic proteins [35]. We observed a 
decreased expression of eIF4E as well as a decreased phosphorylation on S209 in all cases 
of treatment; however, in metastatic cell lines 1205Lu after CQ treatment, the decrease 
in phosphorylation is slight but accompanied by an amazingly low protein level. BRAF 
mutation in melanoma cells results in constitutive activation of the M EK /ER K  pathway 
and activation of M N K 1/2 [43]. A major mechanism for global translational control in­
volves phosphorylation of the a  subunit of eIF2 on S51, which represses the delivery of 
initiator methionyl-tRNA to the translational machinery [34]. Paradoxically, eIF2a phos­
phorylation enhances the translation of selected mRNA, in particular transcription factor 
ATF4, which activates the autophagy genes LC3B and ATG5 [44]. In the absence of eIF2a 
phosphorylation, despite the inhibition of mTORC1, induction of autophagy is not possible 
in amino acid deprivation conditions [45]. This is evidence for eIF2 phosphorylation being 
necessary for autophagy induction. Despite the observed decrease in eIF2 a  expression, 
the phosphorylation at S51 is kept at a relatively high level. Wengrod and colleges have 
shown that mTORC1 regulation of autophagy in melanoma needs eIF2a phosphorylation 
in a pathway independent of U LK 1/2 [45].
ULK1 plays a secondary role in autophagy; monitoring changes in the activity of 
ULK1 is not a direct assay for autophagy activity. Additionally, ULK1 is phosphorylated 
by multiple kinases, and the number of phosphorylation sites can increase or decrease 
during autophagy induction [30]. However, the observed decrease in the phosphoryla­
tion status of ULK1 at inactivating sites (S757) in both tested melanoma cell lines in all 
treatments indicates the existence of autophagy-promoting conditions. The observation of 
downstream targets of mTORC1 did not show a consistent variation in its protein level or 
phosphorylation status in either of the cell lines. siRNA for ILK or CQ may likely affect
the integrity of m TO RCl, and a decreased or increased phosphorylation status of one of 
the TORC1 substrates does not necessarily correlate with changes in others. A decrease of 
m TO RCl activity is a good measure for translation inhibition and autophagy induction; 
however, autophagy may be induced by mTOR-independent mechanisms. Moreover, 
autophagy induction can cause negative feedback that results in the reactivation of mTOR. 
Both RAPTOR and RICTOR may influence autophagy via mTOR. A marked increase in 
both protein levels in metastatic melanoma cell 1205Lu is accompanied by lower autophagy 
induction after silencing of ILK, or by activation of pro-survival signals by an increase 
of Akt phosphorylation resulting from CQ treatment. Furthermore, the ILK /RICTO R 
complex is known to phosphorylate Akt and induce EMT [23,46]. RICTOR is speculated to 
be involved in the development of drug resistance in tyrosine kinase inhibitors therapy [47], 
Perhaps the mTORC2 activation observed as an increase in S2481 phosphorylation is the 
effect of RICTOR's release from the ILK complex after silencing in 1205Lu cells, or the 
activation of mTORC2 is a feedback mechanism to enhance cell survival after CQ treatment. 
The increase in mTORC2 activity may be the reason for the weak influence of CQ on the 
inhibition of migration of 1205 Lu cells. Combinatorial treatment of siRNA for ILK and 
CQ causes both mTORCl and mTORC2 inhibition monitored as phosphorylation on S2448 
and S2481 (Figure 7).
Figure 7. M odel of the signaling pathway in tested m elanoma cells. Red color— inhibition signals, 
black color— stimulation signals. (A) Mechanism of the ILK regulation of translation and autophagy 
in melanoma cells. (B) The influence of siILK and CQ treatment melanoma signaling.
Because ILK is at the heart of the interplay between translation and autophagy, tar­
geting the autophagy machinery by combinatorial treatment with autophagy activator 
(siRNA for ILK) and autophagy inhibitor CQ causes autophagy dysregulation with positive 
anticancer effects. The presented results demonstrated that such an approach produces 
a stronger antitumor effect compared to each treatment used alone. An especially signif­
icant decrease in melanoma cells proliferation was observed. However, the underlying 
mechanism against tumor is ambiguous and does not appear to be dependent on leading 
tumor mutations. Our findings show a complex interaction between signaling pathways 
and activation of alternative compensatory pathways promoting survival triggered by 
autophagy induction or inhibition. Autophagy regulation remains intriguing as a potential 
stand-alone therapeutic strategy or as an enhancer of the sensitivity of cancer cells to other 
conventional drugs.
4. Materials and Methods
4.1. Cell Culture
Human melanoma cell lines: WM793 (vertical growth phase— VGP) and 1205Lu 
(metastatic) cell line was derived from lung metastases of WM793 after subcutaneous injec­
tion into immunodeficient mice. 1205Lu cells are highly invasive and exhibit spontaneous 
metastases to the lung and liver. The BRAFVV600E and loss of PTEN coexist in both 
cell lines. Cells were grown in RPMI-1640 medium supplemented with 10% fetal bovine 
serum and penicillin/streptom ycin (Gibco, Grand Island, NY, USA). Cells were obtained 
from the ESTDAB Melanoma Cell Bank (Tubingen, Germany). All cell lines are tested for 
mycoplasma infection by PCR.
4.2. Cell Culture Treatment
Melanoma cells were grown until 60-70%  confluency was reached, and then trans­
fected using INTERFERin™ as per the m anufacturer's protocol (Polyplus Transfection, 
Illkirch, France) with three different 21bp double-stranded siRNA molecules specifically 
targeting the ILK (Ambion ID#288570; ID#145116; ID#145117) or a control non-silencing 
sequence (Ambion ID#4611) (Thermo Fisher Scientific, Waltham, MA, USA).
For siRNA transfection and scratch wound healing assays, serum-free medium Opti- 
MEM (Gibco, Grand Island, NY, USA) was used. W M793 cells and 1205Lu were in each 
case transfected with 60 nM and 80 nM siRNA, respectively. As transfection control, 
melanoma cells were transfected 19 bp scrambled sequence with 3'dT overhangs. The 
sequences have no significant homology to any known human gene sequences. Because 
no differences were observed between un-transfected cells and silencer negative control 
cells, the latter were selected as control cells in other experiments. After 24 h, the medium 
was replaced with a fresh one and cells were grown for an additional 24 h period with or 
without chloroquine (Sigma-Aldrich, St. Louis, MO, USA) in the final concentration of 
50 gM (48 h post-transfection) before analysis.
4.3. Western Blot Analysis
Cells lysis, Western blot, detection, and visualization of blots were carried out as we 
previously described [21]. Table 1 lists the antibodies and conditions that were used in 
this study. Cell Signaling Technology Inc., Danvers, MA, USA; Transduction Laboratories, 
BD Franklin Lakes, NJ, USA; Sigma-Aldrich, St. Louis, MO, USA; Calbiochem, Merck 
Darmstadt, Germany; MERCK Millipore, Darmstadt, Germany; Santa Cruz Biotechnology, 
Inc., Heidelberg, Germany.
Table 1. Details of primary antibodies used for Western blot analysis.
Primary Antibody Host Species D ilution (A pplication) Vendor
ILK mouse 1:1000 BD Transduction Laboratories
PARP1 mouse 1:1000 Merck
LC 3A /B rabbit 1:1000 Cell Signaling Technology
AM PKa rabbit 1:1000 Cell Signaling Technology
A M PKa Y172 rabbit 1:1000 Cell Signaling Technology
ULK1 rabbit 1:1000 Cell Signaling Technology
ULK1 S555 rabbit 1:1000 Cell Signaling Technology
ULK1 S757 rabbit 1:1000 Cell Signaling Technology
RICTOR rabbit 1:1000 Cell Signaling Technology
RAPTOR rabbit 1:1000 Cell Signaling Technology
mTOR S2448 rabbit 1:1000 Cell Signaling Technology
mTOR S2481 rabbit 1:1000 Cell Signaling Technology
ß-actin mouse 1:12000 Sigma Aldrich
mTOR rabbit 1:1000 Cell Signaling Technology
70S6KY389 rabbit 1:1000 Cell Signaling Technology
70S6K rabbit 1:1000 Santa Cruz Biotechnology
S6 rabbit 1:1000 Santa Cruz Biotechnology
pS6 S235/236 rabbit 1:1000 Cell Signaling Technology
p4E-BP1 rabbit 1:1000 Cell Signaling Technology
Akt S473 rabbit 1:1000 Cell Signaling Technology
Akt mouse 1:500 BD Transduction Laboratories
eIF4E S209 rabbit 1:1000 Cell Signaling Technology
eIF4E rabbit 1:1000 Santa Cruz Biotechnology
pMnK1 rabbit 1:1000 Cell Signaling Technology
MnK1 rabbit 1:1000 Cell Signaling Technology
eIF2a rabbit 1:1000 Santa Cruz Biotechnology
eIF2a S51 rabbit 1:1000 Cell Signaling Technology
4.4. Monitoring Autophagy in the Cell
Autophagy was monitored by sodium sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) and Western blotting with L C 3A /B  antisera. Accumulation of LC3-II, which 
is associated with the number of autophagosome formation, was used as a good marker 
for monitoring autophagy progression. Because that LC3-II is both induced and degraded 
during autophagy, we observed autophagic flux also in the presence of chloroquine (CQ) 
(Sigma-Aldrich, St. Louis, MO, USA), an autophagy inhibitor that prevents the degradation 
of LC3-II and blocks endogenous autophagi flux.
4.5. Proliferation
The proliferation of cells was assessed with the crystal violet test, as previously 
described [48].
4.6. In Vitro Wound Healing/Migration Assay
The in vitro model of wound healing was used to compare the migration of melanoma 
cell lines after transfection of siRNA for ILK and in the presence or absence of CQ. For 
wound healing assay, cells were grown after transfection in serum-free medium Opti-MEM 
until confluent in 24 well plates (24 h). A small linear scratch was created in the confluent 
monolayer by gently scraping with a sterile 1 mL pipette tip. The cells were washed with 
medium to remove cellular debris before treating serum-free Opti-MEM media with or 
without chloroquine in concentration 50 gM. 24 h later, images of the migrated cells were 
taken using a digital camera (Nikon, Tokyo, Japan) connected to the inverted microscope. 
The assay will be repeated thrice in duplicate.
4.7. Statistical Analysis
Shapiro-W ilk W -test was used to check the normality of each variable. Levene's 
test was used for the assessed homogeneity of variance. Statistical analyses of data from 
in vitro studies were performed by one-way analysis of variance (ANOVA) followed by 
Dunnett's post hoc comparison test to determine which values differed significantly from 
the controls. All analyses were made using Statistica 13 software (StatSoft Inc., Tulsa, 
OK, USA). Data were presented as mean ±  SD and considered statistically significant at 
* p < 0.05, ** p < 0.01, and *** p < 0.001.
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